Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
Portfolio Pulse from
Akero Therapeutics announced positive preliminary topline results from its Phase 2b SYMMETRY study, showing significant reversal of compensated cirrhosis (F4) due to MASH. The study found that 39% of patients in the 50mg EFX group showed improvement in fibrosis with no worsening of MASH, a 24% effect size over placebo.
January 27, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics' Phase 2b SYMMETRY study results show significant improvement in fibrosis for MASH patients, with 39% of the 50mg EFX group showing ≥1 stage improvement. This positive outcome could boost investor confidence and impact stock prices favorably.
The positive results from the Phase 2b SYMMETRY study indicate a significant improvement in fibrosis for patients treated with Akero's 50mg EFX. This is a promising development for the company, likely to enhance investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100